Abstract:Background Epigenetic alternation is a common contributing factor to neoplastic transformation. Although previous studies have reported a cluster of aberrant promoter methylation changes associated with silencing of tumor suppressor genes, little is known concerning their sequential DNA methylation changes during the carcinogenetic process. The aim of the present study was to address a genome-wide search for identifying potentially important methylated changes and investigate the onset and pattern of methylation changes during the progression of colorectal neoplasia. Methods A three-phase design was employed in this study. In the screening phase, DNA methylation profile of 12 pairs of colorectal cancer (CRC) and adjacent normal tissues was analyzed by using the Illumina MethylationEPIC BeadChip. Significant CpG sites were selected based on a cross-validation analysis from The Cancer Genome Atlas (TCGA) database. Methylation levels of candidate CpGs were assessed using pyrosequencing in the training dataset (tumor lesions and adjacent normal tissues from 46 CRCs) and the validation dataset (tumor lesions and paired normal tissues from 13 hyperplastic polyps, 129 adenomas, and 256 CRCs). A linear mixed-effects model was used to examine the incremental changes of DNA methylation during the progression of colorectal neoplasia. Results The comparisons between normal and tumor samples in the screening phase revealed an extensive CRC-specific methylomic pattern with 174,006 (21%) methylated CpG sites, of which 22,232 (13%) were hyermethylated and 151,774 (87%) were hypomethylated. Hypermethylation mostly occurred in CpG islands with an overlap of gene promoters, while hypomethylation tended to be mapped far away from functional regions. Further cross validation analysis from TCGA dataset confirmed 265 hypermethylated promoters coupling with downregulated gene expression. Among which, hypermethylated changes in MEEPD2 promoter was successfully replicated in both training and validation phase. Significant hypermethylation appeared since precursor lesions with an extensive modification in CRCs. The linear mixed-effects modeling analysis found that a cumulative pattern of MPPED2 methylation changes from normal mucosa to hyperplastic polyp to adenoma, and to carcinoma ( P < 0.001). Conclusions Our findings indicate that epigenetic alterations of MPPED2 promoter region appear sequentially during the colorectal neoplastic progression. It might be able to serve as a promising biomarker for early diagnosis and stage surveillance of colorectal tumorigenesis.

High-frequency aberrantly methylated targets in pancreatic adenocarcinoma identified via global DNA methylation analysis using methylCap-seq

Genome-wide methylation profiling identified novel differentially hypermethylated biomarker MPPED2 in colorectal cancer

Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma.

Investigation of Aberrantly Methylated Differentially Expressed Genes in Pancreatic Cancer by Integrated Bioinformatics Analysis

Combined Analysis of the Aberrant Epigenetic Alteration of Pancreatic Ductal Adenocarcinoma

Aberrant Methylation in CpG Islands of P15 and P16 Tumor Suppressor Genes in Pancreatic Cancer Tissue

Genome-Wide Analysis Of Differential Methylation In Pancreatic Cancer

Pancreatic cancer differential methylation atlas in blood, peri-carcinomatous and diseased tissue

Aberrant DNA Methylation Patterns of Deleted in Liver Cancer 1 Isoforms in Hepatocellular Carcinoma

Identification of methylation driver genes for predicting the prognosis of pancreatic cancer patients based on whole-genome DNA methylation sequencing technology

Comparative Pan-Cancer DNA Methylation Analysis Reveals Cancer Common and Specific Patterns.

Clinical Significance of Tumor Suppressor Genes Methylation in Circulating Tumor DNA of Patients with Pancreatic Cancer

High-resolution melting analysis of PCDH10 methylation levels in gastric, colorectal and pancreatic cancers.

Integrated Ctdna Methylation Profiling of P2RX1, CBFA2T3, and CERS4 As Pancreatic Ductal Adenocarcinoma Biomarkers: Identification and Mechanistic Insights

Direct ChIP-bisulfite Sequencing Reveals a Role of H3K27me3 Mediating Aberrant Hypermethylation of Promoter CpG Islands in Cancer Cells.

Identification of DNA methylation-driven genes by integrative analysis of DNA methylation and transcriptome data in pancreatic adenocarcinoma.

Revealing distinct DNA methylation patterns in hepatic carcinoma through high-throughput sequencing

Individualized Analysis Reveals Cpg Sites with Methylation Aberrations in Almost All Lung Adenocarcinoma Tissues

Genome‐wide DNA Methylation Patterns in Pancreatic Ductal Adenocarcinoma Reveal Epigenetic Deregulation of SLIT‐ROBO, ITGA2 and MET Signaling

Aberrant Hypermethylation of Tumor Suppressor Genes in Pancreatic Endocrine Neoplasms

Pan-cancer Landscape of Aberrant DNA Methylation Across Childhood Cancers: Molecular Characteristics and Clinical Relevance